Skip to content

Scholar Rock SRRK Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$135K
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
-$573K-267%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$59.33M
Arrowhead Research logo
Arrowhead ResearchARWR
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Segments

By segment

See full
Single Reportable-$3K

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%
Enterprise value$5.45B+82.6%
P/S170.9×

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's gain/loss on asset sales?
Scholar Rock (SRRK) reported gain/loss on asset sales of -$3K in Q1 2026.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.